Fetal safety of erythromycin. An update of Swedish data.

Bengt Källén, Bengt R Danielsson

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

19 Citeringar (SciVal)

Sammanfattning

In previous studies from the Swedish Medical Birth Register, a possible association between erythromycin therapy and an increased risk for cardiovascular defects was found. Other studies using different methodology have not verified this observation. The finding resulted in a warning for the use of erythromycin in early pregnancy, followed by a marked decline in such use. The present study was conducted to follow up on the previous observations and to find methodological explanations for the variation in results in these different published studies.
Originalspråkengelska
Sidor (från-till)355-360
TidskriftEuropean Journal of Clinical Pharmacology
Volym70
Utgåva3
DOI
StatusPublished - 2014

Ämnesklassifikation (UKÄ)

  • Reproduktionsmedicin och gynekologi

Fingeravtryck

Utforska forskningsämnen för ”Fetal safety of erythromycin. An update of Swedish data.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här